Behind The Mystery - Rare and Genetic Diseases Television Special Looking for Participants
Rare diseases get the spotlight on “Behind The Mystery – Rare and Genetic Diseases;” special episodes of The Balancing Act, which airs on Lifetime weekday mornings at 7AM.
The mission of “Behind the Mystery: Rare and Genetic Diseases” is to educate the public about rare and genetic diseases and treatments, and provide support through collaborations in education with pharmaceutical companies, foundations and patient advocacy groups. Partnering with the Global Genes Project, The Balancing Act is the only television show with a special of this kind, working to bring awareness to the plight of rare disease sufferers and the quest for FDA approved treatments and therapies.
The Balancing Act is currently looking for: people from pharmaceutical companies doing research, or working on drug therapies for any of the many rare diseases out there; advocates or representatives from various rare disease group; people who are part of the rare disease world to continue with the series and its mission to be a place when people in the rare disease community can gather for more information.
The special airs every few weeks, past specials are available for viewing here: http://www.thebalancingact.com/rare/
If you’d like to get involved, please contact:
Carri Levy
Senior Associate Producer
The Balancing Act
[email protected]
Related Links:
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
